Baxter (NYSE:BAX) today touted new data demonstrating survival rate improvements with its Sharesource digital health platform. Deerfield, Illinois–based Baxter presented data during the American Society of Nephrology’s annual Kidney Week that took place last week, according to a news release. Baxter designed its Sharesource remote patient management digital health platform for use in helping to […]
Baxter
Medtech M&A: The industry’s biggest mergers and acquisitions of 2021
Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more. Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired. Here are the 10 biggest mergers and acquisitions in medtech in […]
Hillrom posts Street-beating Q4 as Baxter merger remains on track
Hillrom (NYSE:HRC) shares were relatively unmoved on fourth-quarter results that finished well ahead of the consensus forecast. The Chicago-based connected care technology developer posted profits of $53.4 million, or 80¢ per share, on sales of $797.9 million for the three months ended Sept. 30, 2021, for a 25.9% bottom-line gain on sales growth of 13.1%. […]
Baxter beats EPS consensus, matches revenue estimates in Q3
Baxter (NYSE:BAX) today posted third-quarter results that beat the overall consensus on Wall Street. The Deerfield, Illinois-based company reported profits of $452 million, or 89¢ per share, on sales of $3.23 billion for the three months ended September 30, for a bottom-line gain of 25.9% on sales growth of 8.55% compared with Q3 2020. Adjusted to […]
Baxter, Biomérieux win CE mark for test predicting persistent severe acute kidney injury
Baxter (NYSE:BAX) and Biomérieux (EPA:BIM) today announced CE mark approval for their Nephroclear CCL14 test. The companies designed the Nephroclear CCL14 test to predict persistent severe acute kidney injury (PS-AKI). It can be used to support timely clinical decision-making and care pathways, according to a news release. Baxter and Biomérieux plan to launch Nephroclear CCL […]
Baxter warns on some PrisMax hemodialysis machines
Baxter (NYSE:BAX) issued a device correction in Europe for its PrisMax hemodialysis machine due to a software anomaly. The correction relates to a software anomaly occurring during use. If the operator initiates therapy with a saved prescription profile and makes a change to the prescription after a disposable filter change using the “Same Patient” button, […]
Hillrom’s business outlook is better-than-expected as Baxter prepares to acquire
Analysts are pleased with Hillrom’s (NYSE:HRC) position following a proxy statement last week as it nears its merger with Baxter (NYSE:BAX). Baxter announced last month that it agreed to buy Hillrom for approximately $12.4 billion, with Hillrom shareholders set to receive $156 per common stock share as the company will survive the merger as a […]
FDA approves Baxter’s norepinephrine injection for treating low blood pressure
Baxter (NYSE:BAX) announced today that it received FDA approval for its premix norepinephrine bitartrate in 5% dextrose injection. Deerfield, Illinois-based Baxter launched the norepinephrine injection following the approval for raising blood pressure in adult patients with severe, acute hypotension (low blood pressure). Get the full story at our sister site, Drug Delivery Business News.
Baxter to acquire Hillrom for $12.4B
Baxter (NYSE:BAX) announced today that it entered into a definitive agreement to acquire Hillrom (NYSE:HRC) for approximately $12.4 billion. Rumblings of a potential deal surfaced earlier this week, leading to a massive rise for Hillrom’s stock. The expectation was that the companies would reach a deal by midweek so long as talks didn’t fall apart. Those […]
Hillrom stock skyrockets amid reports that Baxter is close to acquisition
Baxter (NYSE:BAX) is reportedly in advanced talks to acquire Hillrom (NYSE:HRC) for approximately $10 billion. The Wall Street Journal reported yesterday that the talks were ongoing at an advanced stage. WSH previously reported on rumblings of a potential deal last month. Hillrom’s stock shot up when that report came out, and it’s rising again today, […]
Baxter working on software upgrade for serious Spectrum IQ problems
Baxter (NYSE:BAX) this week issued an urgent medical device correction for all of its Spectrum IQ infusion pumps. Earlier this month, FDA designated a recall of Baxter’s Dose IQ safety software program as Class I, its most serious level. Baxter designed the Dose IQ as a standalone computer-based software program that allows care providers to create […]